Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Kavita Venugcpal Nair

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-DOCP General Operations
Phone303/724-2635

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. DiStefano MJ, Dardouri M, Moore GD, Saseen JJ, Nair KV. Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado. J Pharm Policy Pract. 2025; 18(1):2441220. PMID: 39776466.
      View in: PubMed
    2. Carlson AM, Sollero CEV, Wolf AB, Sillau S, Schmitt BL, Money KM, Nair KV, Piquet AL, Bennett JL. The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population. Ann Clin Transl Neurol. 2025 Jan; 12(1):169-179. PMID: 39708292.
      View in: PubMed
    3. Crane PD, Sillau S, Dreher R, Fix R, Winters P, Van Coevering R, Engebretson E, Valdez B, Matthews E, Nair KV, Carlson AM, Piquet AL. Population-Based Study of the Epidemiology of Stiff Person Syndrome in a Large Colorado-Based Health System. Neurology. 2024 Dec 24; 103(12):e210078. PMID: 39621949.
      View in: PubMed
    4. Kammeyer R, Chapman K, Furniss A, Hsieh E, Fuhlbrigge R, Ogbu EA, Boackle S, Zell J, Nair KV, Borko TL, Cooper JC, Bennett JL, Piquet AL. Blood-based biomarkers of neuronal and glial injury in active major neuropsychiatric systemic lupus erythematosus. Lupus. 2024 Sep; 33(10):1116-1129. PMID: 39148457.
      View in: PubMed
    5. DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180. PMID: 37961908.
      View in: PubMed
    6. Nair KV, Stuursma L, Eigenbrod M, Cremeen D, Ahmed A. Gold Carding Policies: Reducing the Barriers Between Payers and Providers. Neurol Clin Pract. 2024 Apr; 14(2):e200256. PMID: 38223350.
      View in: PubMed
    7. Wilson AM, Lundgren KB, Schierman B, Mante A, Lien A, Benish SM, Esper GJ, Nair KV, Ney JP. Examining the National Representativeness of the Axon Registry: A Neurology-Specific Patient Registry. Neurology. 2023 09 12; 101(11):e1167-e1177. PMID: 37487753.
      View in: PubMed
    8. Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-Gonz?lez J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. Ann Clin Transl Neurol. 2023 04; 10(4):579-588. PMID: 36811392.
      View in: PubMed
    9. Nair KV. Role of the Bruton tyrosine kinase pathway in multiple sclerosis. Am J Manag Care. 2022 12; 28(16 Suppl):S323-S328. PMID: 36548523.
      View in: PubMed
    10. McQueen RB, Mendola ND, Jakab I, Bennett J, Nair KV, N?meth B, Inotai A, Kal? Z. Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods. Pharmacoecon Open. 2023 Mar; 7(2):217-228. PMID: 36316575.
      View in: PubMed
    11. Coerver K, Yu MM, D'Abreu A, Wasserman M, Nair KV. Practical Considerations in the Administration of Aducanumab for the Neurologist. Neurol Clin Pract. 2022 Apr; 12(2):169-175. PMID: 35733944.
      View in: PubMed
    12. Kammeyer R, Mizenko C, Sillau S, Richie A, Owens G, Nair KV, Alvarez E, Vollmer TL, Bennett JL, Piquet AL. Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders. Front Neurol. 2022; 13:689975. PMID: 35309573.
      View in: PubMed
    13. Vollmer TL, Nair KV, Williams IM, Alvarez E. Multiple Sclerosis Phenotypes as a Continuum: The Role of Neurologic Reserve. Neurol Clin Pract. 2021 Aug; 11(4):342-351. PMID: 34476126.
      View in: PubMed
    14. Toosy AT, Kapur K, Nair KV. Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet? Neurology. 2021 05 18; 96(20):927-928. PMID: 33827959.
      View in: PubMed
    15. de Havenon A, Delic A, Dehoney S, Whetman P, Sheibani N, Callaghan B, Ney J, Esper GJ, Magliocco B, Nair KV. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D. Neurology. 2021 04 20; 96(16):e2132-e2137. PMID: 33692164.
      View in: PubMed
    16. Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102454. PMID: 33045496.
      View in: PubMed
    17. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals With Chronic Disease. J Manag Care Spec Pharm. 2020 May; 26(5):575-585. PMID: 32347176.
      View in: PubMed
    18. McQueen RB, Farahbakhshian S, Bell KF, Nair KV, Saseen JJ. Economic burden of comorbid chronic kidney disease and diabetes. J Med Econ. 2017 Jun; 20(6):585-591. PMID: 28128669.
      View in: PubMed
    19. McQueen RB, Ghushchyan V, Olufade T, Sheehan JJ, Nair KV, Saseen JJ. Incremental increases in economic burden parallels cardiometabolic risk factors in the US. Diabetes Metab Syndr Obes. 2016; 9:233-41. PMID: 27536152.
      View in: PubMed
    20. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016 Mar 15; 86(11):1014-21. PMID: 26888980.
      View in: PubMed
    21. Page RL, Ghushchyan V, Van Den Bos J, Gray TJ, Hoetzer GL, Bhandary D, Nair KV. The cost of inpatient death associated with acute coronary syndrome. Vasc Health Risk Manag. 2016; 12:13-21. PMID: 26893568.
      View in: PubMed
    22. McQueen RB, Nair KV, Vollmer TL, Campbell JD. Incorporating real-world clinical practice in multiple sclerosis economic evaluations. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):869-72. PMID: 26295727.
      View in: PubMed
    23. Saseen JJ, Ghushchyan V, Nair KV. Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population. J Clin Hypertens (Greenwich). 2015 Feb; 17(2):134-40. PMID: 25496048.
      View in: PubMed
    24. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Campbell JD. Frequency of Continuous Glucose Monitoring Use and Change in Hemoglobin A1C for Adults with Type 1 Diabetes in a Clinical Practice Setting. Endocr Pract. 2014 Oct; 20(10):1007-15. PMID: 24793924.
      View in: PubMed
    25. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, Campbell JD. Association between glycated hemoglobin and health utility for Type 1 diabetes. Patient. 2014; 7(2):197-205. PMID: 24458545.
      View in: PubMed
    26. Saseen JJ, Ghushchyan V, Kaila S, Allen RR, Nair KV. Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers. J Clin Hypertens (Greenwich). 2013 Dec; 15(12):888-92. PMID: 24102728.
      View in: PubMed
    27. Libby AM, Fish DN, Hosokawa PW, Linnebur SA, Metz KR, Nair KV, Saseen JJ, Vande Griend JP, Vu SP, Hirsch JD. Patient-level medication regimen complexity across populations with chronic disease. Clin Ther. 2013 Apr; 35(4):385-398.e1. PMID: 23541707.
      View in: PubMed
    28. Nair KV, Naim AB, Draaghtel K, Van Den Bos J. Work absences and expenditures for employees with autoimmune inflammatory diseases. J Occup Environ Med. 2012 Oct; 54(10):1268-74. PMID: 22995815.
      View in: PubMed
    29. Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, Nair KV. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012 Nov; 51(11):2004-12. PMID: 22829689.
      View in: PubMed
    30. Page RL, Ghushchyan V, Allen RR, Roper L, Beck D, Jonathan BH, Frech-Tamas F, Chan W, McQueen RB, Nair KV. Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap. Drug Healthc Patient Saf. 2012; 4:67-74. PMID: 22826644.
      View in: PubMed
    31. Alford JC, Saseen JJ, Allen RR, Nair KV. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. Pharmacotherapy. 2012 Jul; 32(7):623-30. PMID: 22570173.
      View in: PubMed
    32. Abbott ZI, Nair KV, Allen RR, Akuthota VR. Utilization characteristics of spinal interventions. Spine J. 2012 Jan; 12(1):35-43. PMID: 22138113.
      View in: PubMed
    33. McQueen RB, Ellis SL, Campbell JD, Nair KV, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc. 2011 Sep 14; 9:13. PMID: 21917132.
      View in: PubMed
    34. Nair KV, Corboy J, Kahler K, Allen RR, Ghushcyan V, McQueen RB, Bainbridge J, Dastani H, Mody-Patel N. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. Expert Rev Neurother. 2011 Jun; 11(6):787-98. PMID: 21651327.
      View in: PubMed
    35. Nair KV, Frech-Tamas F, Jan S, Wolfe P, Allen RR, Saseen JJ. Comparing pre-gap and gap behaviors for Medicare beneficiaries in a Medicare managed care plan. J Health Care Finance. 2011; 38(2):38-53. PMID: 22372031.
      View in: PubMed
    36. Nair KV, Miller K, Park J, Allen RR, Saseen JJ, Biddle V. Prescription co-pay reduction program for diabetic employees. Popul Health Manag. 2010 Oct; 13(5):235-45. PMID: 20879904.
      View in: PubMed
    37. Bhardwaja B, Carroll N, Korner E, Nair KV. Impact of prescription benefit coverage limits on sevelamer hydrochloride adherence for patients with ESRD. Am Health Drug Benefits. 2009 Sep; 2(6):242-50. PMID: 25126297.
      View in: PubMed
    38. Nair KV, Park J, Wolfe P, Saseen JJ, Allen RR, Ganguly R. Consumer-driven health plans: impact on utilization and expenditures for chronic disease sufferers. J Occup Environ Med. 2009 May; 51(5):594-603. PMID: 19369897.
      View in: PubMed
    39. Nair KV, Tang B, Van Den Bos J, Zhang V, Saseen JJ, Naim A, Rahman M. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin. 2009 Feb; 25(2):303-14. PMID: 19192975.
      View in: PubMed
    40. Nair KV, Miller K, Saseen J, Wolfe P, Allen RR, Park J. Prescription copay reduction program for diabetic employees: impact on medication compliance and healthcare costs and utilization. Am Health Drug Benefits. 2009 Jan; 2(1):14-24. PMID: 25126268.
      View in: PubMed
    41. Nair KV, Saseen JJ. Quality assessment of dyslipidemia in managed care: current best evidence should be used to benchmark quality. Ann Pharmacother. 2006 Jan; 40(1):124-7. PMID: 16368926.
      View in: PubMed
    42. Sullivan PW, Nair KV, Patel BV. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. Am J Manag Care. 2005 Jun; 11(6):374-82. PMID: 15974556.
      View in: PubMed
    43. Nair KV, Sullivan PW. Therapeutic and economic consequences of OTC loratadine. Ann Pharmacother. 2004 Jan; 38(1):169-71. PMID: 14742815.
      View in: PubMed
    44. Valuck RJ, Williams SA, MacArthur M, Saseen JJ, Nair KV, McCollum M, Ensor JE. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther. 2003 Nov; 25(11):2936-57. PMID: 14693317.
      View in: PubMed
    45. Nair KV. Do consumers' attitudes predict prescription purchasing behavior? Manag Care Interface. 2003 Jun; 16(6):22-7, 55. PMID: 12841073.
      View in: PubMed
    46. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm. 2003 Mar-Apr; 9(2):123-33. PMID: 14613341.
      View in: PubMed
    47. Nair KV, Ganther JM, Valuck RJ, McCollum MM, Lewis SJ. Impact of multi-tiered pharmacy benefits on attitudes of plan members with chronic disease states. J Manag Care Pharm. 2002 Nov-Dec; 8(6):477-91. PMID: 14613381.
      View in: PubMed
    48. Nair KV. Evaluation of health and pharmacy benefit information in health plan information packages. Manag Care Interface. 2001 Dec; 14(12):51-4. PMID: 11794843.
      View in: PubMed
    Nair's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (204) concept(s)
    _
    Co-Authors Expand Description
    See all (25) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)